PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18347158-0	2008	Preclinical modeling of cytosine arabinoside response in Mll-Enl translocator mouse leukemias.	Cytarabine	24-44	lysine (K)-specific methyltransferase 2A	Mus musculus	57-60	
34627412-11	2021	Experimental treatment was carried out on the leukemia mouse model transplanted with MLL-AF9 spleen cells, and it was found that the traditional chemotherapy drug cytarabine could delay the onset of leukemia and prolong the survival time of the mouse model.	Cytarabine	163-173	lysine (K)-specific methyltransferase 2A	Mus musculus	85-88	
30967619-3	2019	Both alleles cooperated with Mll-Af9 to accelerate leukemia development that resulted in resistance to standard Cytarabine-based chemotherapy.	Cytarabine	112-122	lysine (K)-specific methyltransferase 2A	Mus musculus	29-32	
34080665-2	2021	Previous findings with a mouse model showed that cooperation of MLL/AF10 with tyrosine-protein phosphatase non-receptor type 11 (PTPN11)G503A accelerated leukemia development, but increased cytarabine (Ara-C) sensitivity of leukemia cells.	Cytarabine	190-200	lysine (K)-specific methyltransferase 2A	Mus musculus	64-67	
34080665-2	2021	Previous findings with a mouse model showed that cooperation of MLL/AF10 with tyrosine-protein phosphatase non-receptor type 11 (PTPN11)G503A accelerated leukemia development, but increased cytarabine (Ara-C) sensitivity of leukemia cells.	Cytarabine	202-207	lysine (K)-specific methyltransferase 2A	Mus musculus	64-67